Azizi M, et al. - In the RADIANCE-HTN SOLO trial—which assigned patients not treated with antihypertensive medications to endovascular ultrasound renal denervation (RDN) or a sham procedure—researchers report the 6-month outcomes after addition of a recommended standardized stepped-care antihypertensive treatment (SSAHT) to the randomized endovascular procedure under continued blinding to initial treatment. Ambulatory blood pressure (BP) measurements were obtained for 6 months in 69 of 74 RDN patients and 71 of 72 sham patients. At 6 months, 65.2% and 84.5% of patients in the RDN group and in the sham group, respectively, received the SSAHT. The mean number of antihypertensive drugs and defined daily dose were fewer in the RDN vs sham group. Overall, endovascular ultrasound RDN continued to offer BP lowering effect at 6 months with fewer prescribed antihypertensive medications than with the sham control.